Targeted protein degradation (TPD) has emerged as a potent drug modality, using bispecific small molecules to remove intracellular proteins by recruiting them to E3 ligases for proteasomal degradation. Unlike traditional drugs, TPD works catalytically, potentially offering greater effectiveness and sustained action with lower doses. Recently, this approach has expanded to extracellular proteins through extracellular targeted protein degradation (eTPD) using bispecific antibodies or small molecules, broadening therapeutic targets and applications.

Extracellular targeted protein degradation

Advantages of Choosing LifeSensors for your Degrader Drug Discovery

  • Study PROTAC and degrader mediated Ubiquitination and Degradation simultaneously
  • Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
  • Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
  • Proteomics to characterize protein degradation – establish selectivity

With deep and diverse expertise in medicinal chemistry, biochemistry, and cell-biology specializing in ubiquitin based drug discovery  for the last 15 years, LifeSensors is proud to offer efficient methods to accelerate your discovery of novel molecules facilitating targeted protein degradation. We offer our degrader discovery services starting from design and synthesis of novel PROTACs, to monitoring PROTAC binding to target and E3 ligases (biochemical and biophysical), including functional ubiquitination and degradation assays in cells. PROTAC-mediated ubiquitylation in vitro permits rapid screening of compound libraries and allows simplification of the medicinal chemistry approach to rationally design potent molecules. Your biochemists can focus on new PROTAC targets as LifeSensors will translate its core technologies for in vitro and cellular PROTAC screens.